Shield Therapeutics (LON:STX) Shares Cross Below Fifty Day Moving Average – What’s Next?

Shield Therapeutics plc (LON:STX) shares passed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of GBX 5.25 and traded as low as GBX 2.93. Shield Therapeutics shares last traded at GBX 3.05, with a volume of 41,407,309 shares.

Shield Therapeutics Trading Up 7.9%

The company has a fifty day simple moving average of GBX 5.25 and a 200-day simple moving average of GBX 6.96. The company has a current ratio of 0.75, a quick ratio of 2.16 and a debt-to-equity ratio of -146.28. The stock has a market cap of £35.34 million, a price-to-earnings ratio of -3.29 and a beta of 1.77.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.